TScan Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 23, 2024, covering events occurring on December 20, 2024. TScan Therapeutics, Inc. (TCRX), a Delaware corporation, entered into a new material definitive agreement to refinance its existing debt obligations and secure additional liquidity for general corporate purposes.
Key Financial Metrics and Debt Structure
- New Debt Facility: Entered into a Loan and Security Agreement with Silicon Valley Bank for a total term loan facility of up to $52.5 million.
- Initial Funding: A first tranche of $32.5 million was fully funded on the effective date.
- Contingent Funding: A second tranche of $20.0 million is available at the lender's sole discretion on or prior to June 30, 2026.
- Interest Rate: The greater of 7.00% or the prime rate minus 0.75%, capped at 9.75% per annum.
- Repayment Terms: Monthly interest-only payments until September 30, 2027, contingent on achieving financial and clinical milestones. If milestones are not met by June 30, 2026, the maturity date shortens to September 1, 2028, and amortization begins September 30, 2026.
- Exit Fee: A final payment equal to 5.0% of the aggregate original principal amount is due at maturity or acceleration.
- Prepayment Penalties: 3.0% in the first year, 2.0% in the second year, and 1.0% thereafter.
- Collateral: First-priority security interest on substantially all company assets (excluding intellectual property).
Material Changes Versus Prior Period
The Company terminated its existing Loan and Security Agreement dated September 9, 2022. All outstanding obligations under the prior agreement, totaling $17.2 million, were repaid using proceeds from the new facility. The Company incurred an aggregate exit fee and prepayment premium of $2.1 million to terminate the prior agreement. All security interests and guarantees associated with the old loan were released.
Outlook, Risks, and Covenants
- Covenants: The agreement includes affirmative and negative covenants restricting asset disposal, business changes, mergers, additional indebtedness, liens, dividends, equity repurchases, and affiliate transactions. Notably, there is no financial maintenance covenant.
- Acceleration Risks: The term loans automatically accelerate upon bankruptcy or insolvency events. Failure to meet financial and clinical milestones by June 30, 2026, will alter the maturity date and amortization schedule.
- Management Commentary: Proceeds from the initial tranche were used to refinance the existing loan, with the remainder allocated to general corporate purposes.
Investor Verification Checklist
- Verify the specific financial and clinical milestones required to maintain the September 2029 maturity date and extended interest-only period.
- Confirm the Company's current cash position and burn rate to assess the runway provided by the $32.5 million initial tranche.
- Review the full text of the Loan and Security Agreement (Exhibit 10.1) for detailed definitions of restricted transactions and thresholds.
- Monitor the Company's progress toward the milestones with a June 30, 2026 deadline to avoid an earlier maturity date.
- Assess the impact of the 5.0% final payment and potential prepayment fees on future liquidity and refinancing costs.